[
    [
        {
            "time": "2018-03-15",
            "original_text": "Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy",
            "features": {
                "keywords": [
                    "Teva",
                    "Gains",
                    "Positive",
                    "CHMP",
                    "Opinion",
                    "Migraine",
                    "Drug",
                    "Ajovy"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "What's in the Cards for Glaxo (GSK) This Earnings Season?",
            "features": {
                "keywords": [
                    "Glaxo",
                    "GSK",
                    "Earnings",
                    "Season"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Better Buy: Johnson & Johnson vs. Merck & Co.",
            "features": {
                "keywords": [
                    "Better",
                    "Buy",
                    "Johnson",
                    "&",
                    "Johnson",
                    "vs.",
                    "Merck",
                    "&",
                    "Co."
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Novartis Backs Lutathera Pricing After Price-Gouging Accusations",
            "features": {
                "keywords": [
                    "Novartis",
                    "Backs",
                    "Lutathera",
                    "Pricing",
                    "Price-Gouging",
                    "Accusations"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novartis Backs Lutathera Pricing After Price-Gouging Accusations",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]